Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (5)
  • Open Access

    ARTICLE

    MINDY1 Induces PD-L1 Deubiquitination to Promote Immune Escape in Hepatocellular Carcinoma by the Wnt/β-Catenin Pathway

    Xingchao Song1,#, Qiuyu Song2,#, Xiao Ma1, Anzhi Xu1, Chunyan Tian1,*

    Oncology Research, Vol.33, No.11, pp. 3583-3603, 2025, DOI:10.32604/or.2025.067638 - 22 October 2025

    Abstract Background: Motif interacting with ubiquitin-containing novel DUB family-1 (MINDY1) could enhance the stability of programmed death-ligand 1 (PD-L1). The study aimed to investigate whether MINDY1 regulates the immune escape of hepatocellular carcinoma (HCC) mediated by PD-L1. Methods: MINDY1 and PD-L1 levels were detected through Western blot. The link between MINDY1 and PD-L1 was validated using the co-immunoprecipitation assay. The malignant biology of HCC cells was assessed through Cell Counting Kit-8, Carboxyfluorescein Succinimidyl Ester staining, transwell, and wound healing assay. CD8+ T cells were isolated and then co-cultured with HCC cells. Enzyme-linked immunosorbent Assay kits detected CD8+More > Graphic Abstract

    MINDY1 Induces PD-L1 Deubiquitination to Promote Immune Escape in Hepatocellular Carcinoma by the Wnt/β-Catenin Pathway

  • Open Access

    REVIEW

    Non-coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy

    JIAHUI WANG1,#, HONGCHENG GE2,3,#, ZHENGYUAN YU1,*, LINGZHI WU1,*

    Oncology Research, Vol.33, No.5, pp. 1033-1054, 2025, DOI:10.32604/or.2024.058256 - 18 April 2025

    Abstract Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes More >

  • Open Access

    ARTICLE

    Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer

    SHIQIN JIANG1,#, YICHUN TANG2,#, FENG MA3, YUCHUN NIU4,*, LEI SUN5,*

    Oncology Research, Vol.33, No.1, pp. 213-224, 2025, DOI:10.32604/or.2024.046895 - 20 December 2024

    Abstract Objective: Small cell lung cancer (SCLC) is commonly recognized as the most fatal lung cancer type. Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers, their benefits are limited to a minority of patients with SCLC. In the present study, novel indicators for predicting the outcomes and molecular targets for SCLC treatment were elucidated. Methods: We conducted bioinformatics analysis to identify the key genes associated with tumor-infiltrating lymphocytes in SCLC. The functional role of the key gene identified in SCLC was determined both in vitro and in vivo. Results: A significant correlation was observed between… More >

  • Open Access

    ARTICLE

    The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma

    RUI ZHANG1,2,#, PENG ZHOU1,3,#, XIA OU4, PEIZHU ZHAO2, XIJING GUO2, MIAN XI5,*, CHEN QING1,*

    Oncology Research, Vol.31, No.6, pp. 887-897, 2023, DOI:10.32604/or.2023.030184 - 15 September 2023

    Abstract Esophageal squamous cell carcinoma (ESCC) is among the most prevalent causes of cancer-related death in patients worldwide. Resistance to immunotherapy and chemotherapy results in worse survival outcomes in ESCC. It is urgent to explore the underlying molecular mechanism of immune evasion and chemoresistance in ESCC. Here, we conducted RNA-sequencing analysis in ten ESCC tissues from cisplatin-based neoadjuvant chemotherapy patients. We found that DMRTA1 was extremely upregulated in the non-pathologic complete response (non-pCR) group. The proliferation rate of esophageal squamous carcinoma cells was markedly decreased after knockdown of DMRTA1 expression, which could increase cisplatin sensitivity in More >

  • Open Access

    REVIEW

    Scaffold proteins of cancer signaling networks: The paradigm of FK506 binding protein 51 (FKBP51) supporting tumor intrinsic properties and immune escape

    LAURA MARRONE1, MASSIMO D’AGOSTINO1, CAROLINA GIORDANO2, VALERIA DI GIACOMO1, SIMONA URZINI1, CHIARA MALASOMMA1, MARIA PAOLA GAMMELLA1, MARTINA TUFANO1, SIMONA ROMANO1,*, MARIA FIAMMETTA ROMANO1,*

    Oncology Research, Vol.31, No.4, pp. 423-436, 2023, DOI:10.32604/or.2023.028392 - 25 June 2023

    Abstract Scaffold proteins are crucial regulators of signaling networks, and their abnormal expression may favor the development of tumors. Among the scaffold proteins, immunophilin covers a unique role as ‘protein-philin’ (Greek ‘philin’ = friend) that interacts with proteins to guide their proper assembly. The growing list of human syndromes associated with the immunophilin defect underscores the biological relevance of these proteins that are largely opportunistically exploited by cancer cells to support and enable the tumor’s intrinsic properties. Among the members of the immunophilin family, the FKBP5 gene was the only one identified to have a splicing variant. More > Graphic Abstract

    Scaffold proteins of cancer signaling networks: The paradigm of FK506 binding protein 51 (FKBP51) supporting tumor intrinsic properties and immune escape

Displaying 1-10 on page 1 of 5. Per Page